May 30 |
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD)
|
May 28 |
BioLineRx Ltd. (BLRX) Q1 2024 Earnings Call Transcript
|
May 28 |
biolinerx GAAP EPS of $0.00 beats by $0.29, revenue of $6.86M beats by $6.52M
|
May 28 |
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates
|
May 24 |
biolinerx Q1 Earnings Preview
|
May 24 |
BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
|
May 22 |
BioLineRx to Report First Quarter 2024 Results on May 28, 2024
|
May 17 |
BioLineRx receives Nasdaq minimum bid price notification
|
May 17 |
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
|
May 6 |
BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024
|